Tang Capital Partners, LP v. Cell Therapeutics, Inc.

591 F. Supp. 2d 666, 2008 U.S. Dist. LEXIS 104822, 2008 WL 5336393
CourtDistrict Court, S.D. New York
DecidedDecember 17, 2008
Docket08 Civ. 0017(CM)(DCF)
StatusPublished
Cited by4 cases

This text of 591 F. Supp. 2d 666 (Tang Capital Partners, LP v. Cell Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Tang Capital Partners, LP v. Cell Therapeutics, Inc., 591 F. Supp. 2d 666, 2008 U.S. Dist. LEXIS 104822, 2008 WL 5336393 (S.D.N.Y. 2008).

Opinion

DECISION AND ORDER DENYING DEFENDANT’S SUGGESTION THAT THE COURT LACKS JURISDICTION TO ENTERTAIN PLAINTIFF’S APPLICATION FOR A PRELIMINARY INJUNCTION, DECLINING TO ENTER A TEMPORARY RESTRAINING ORDER, AND DIRECTING A HEARING ON PLAINTIFF’S APPLICATION FOR PRELIMINARY INJUNCTION AND ON THE ISSUE OF JURY TRIAL WAIVER

McMAHON, District Judge:

Introduction

On December 10, 2008, plaintiff Tang Capital Partners, LP (“Tang Capital”) filed an application for a temporary restraining order (“TRO”) under Federal Rule of Civil Procedure 65 against defendant Cell Therapeutics, Inc. (“CTI”). Tang Capital’s request for a TRO is connected to the present litigation before this Court — based on Diversity — on a breach of contract claim.

*667 Plaintiffs application requests that CTI be enjoined from “committing yet another breach of the parties’ stock purchase contract ... [by] acquiring certain outstanding convertible debt by way of a Dutch Auction.” (PI. Application for a TRO at 1.) Tang Capital asserts that a TRO is warranted because “CTI’s conduct will result in immediate and irreparable injury, losses and damage to Tang Capital. If CTI is permitted to complete its newly-proposed transaction, CTI, which has never been profitable, will lack sufficient capital to pay Tang Capital under the redemption procedure of the parties’ contract.” (Id.)

CTI submitted a brief written response to Tang Capital’s application the following day, December 11th, and the Court held an immediate hearing "with all parties at which we discussed the TRO and CTI’s suggestion that the court lacked jurisdiction to entertain the application for injunc-tive relief. After hearing arguments from both sides, this Court asked the parties to submit supplemental briefs on two issues: whether this Court has the jurisdiction to entertain an application for a TRO in this case in light of the Supreme Court’s decision in Grupo Mexicano de Desarrollo S.A. v. Alliance Bond Fund, Inc., 527 U.S. 308, 119 S.Ct. 1961, 144 L.Ed.2d 319 (1999); and whether Tang Capital had waived the waiver of jury trial to which the parties agreed in their contract by demanding a jury trial in its complaint against CTI.

I conclude that the Court has jurisdiction to entertain plaintiffs application for a preliminary injunction. There is no need to enter a TRO at this time, because defendant has represented to the Court that the proposed transaction being challenged by plaintiff will not be consummated until January 12 at the earliest, and the parties have already been ordered to appear at a hearing on plaintiffs motion for a preliminary injunction on January 6, 2009. At that hearing, I will also take evidence on whether, by demanding a jury trial, plaintiff “waived the waiver” of jury trial that is a term of the contract between the parties.

Background

Tang Capital is a Delaware limited partnership and registered investment fund; its headquarters are in San Diego, California. Tang Capital invests in public and private health care and biotechnology companies through private placements. It also regularly purchases equity or debt securities on the open market.

Kevin Tang (“Tang”) is the managing director of Tang Capital Management, LLC, which is the general partner of Tang Capital. Tang is responsible for all of the investment decisions made by Tang Capital.

CTI is a Washington corporation with its headquarters in Seattle. CTI is a biotechnology company that develops cancer therapies. It became a public company in 1997.

The principal founder of CTI is Dr. James Bianco (“Dr. Bianco”). He is the corporation’s chief executive officer and serves as a director.

In or about April 2007, Tang Capital purchased 3,000 shares of CTI’s Series B Preferred Stock (hereinafter, “the Stock”) for $3 million. In order to purchase the Stock, a purchaser needed to execute a Series B Purchase Agreement (hereinafter, “Purchase Agreement”) and Articles of Amendment to Amended and Restated Articles of Incorporation (hereinafter, “Restated Articles”) (collectively, the “Transaction Documents”). The purchase of the Stock pursuant to the terms of the Transaction Documents forms the basis for Tang Capital’s breach of contract claim and its application for a TRO.

*668 For the purposes of this decision, the relevant provisions of the Restated Articles are: (1) the definition of “Common Stock Equivalent”; (2) the definition of “Triggering Redemption Amount”; (3) Section 9: “Redemption Upon Triggering Events”; and (4) Section 10: “Negative Covenants.” The relevant provisions of the Purchase Agreement are: (1) “5.15: Remedies”', and (2) “5.9 Governing Law.”

At the time the Transaction Documents were signed the term “Common Stock Equivalent” was defined as follows:

any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

(Tang Decl. Ex. A at CTI-TC0000441).

A “Triggering Event,” for our purposes, is defined as the failure by CTI “to observe or perform any covenant, agreement or warranty contained in, or otherwise commit any breach of, the Transaction Documents ....” (Id. at CTI-TC0000456.) The specific contractual covenant at issue is:

Section 10. Negative Covenants. So long as any shares of Series B Preferred Stock are outstanding, unless the holders of at least 67% in the Stated Value of the then outstanding shares of the Series B Preferred Stock shall have otherwise given prior written consent, the Corporation shall not, and shall not permit any of its subsidiaries (whether or not a Subsidiary on the Original Issue Date) to, directly or indirectly: ... b) repay, repurchase or offer to repay, repurchase or otherwise acquire any shares of its Common Stock, Common Stock Equivalents or Junior Securities

(Id. at CTI-TC0000457.)

If a “Triggering Event” occurred, a Holder of the Stock was entitled “to require the Corporation to redeem all of the Series B Preferred Stock then held by such Holder for a redemption price equal to the Triggering Redemption Amount.” (Id. at CTI-TC0000457.) The “Triggering Redemption Amount” is

for each share of Series B Preferred Stock, the sum of (i) the greater of (A) 130% of the Stated Value and (B) the product of (a) the VWAP on the Trading Day immediately preceding the date of the Triggering Event and (b) the Stated Value divided by the then Conversion Price, (ii) all accrued but unpaid dividends thereon and (iii) all liquidated damages and other costs, expenses or amounts due in respect of the Series B Preferred Stock.

(Id. at CTI-TC0000443-44.)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
591 F. Supp. 2d 666, 2008 U.S. Dist. LEXIS 104822, 2008 WL 5336393, Counsel Stack Legal Research, https://law.counselstack.com/opinion/tang-capital-partners-lp-v-cell-therapeutics-inc-nysd-2008.